Đang chuẩn bị liên kết để tải về tài liệu:
Nivolumab plus ipilimumab versus nivolumab in individuals with treatmentnaive programmed death-ligand 1 positive metastatic soft tissue sarcomas: A multicentre retrospective study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Currently, the choice of treatment for individuals with metastatic soft tissue sarcomas (MSTS) presents a significant challenge to clinicians. The aim of this retrospective study was to assess the efficacy and safety of nivolumab plus ipilimumab (NPI) versus nivolumab alone (NIV) in individuals with treatment-naive programmed death-ligand 1 (PD-L1) positive MSTS. |

TÀI LIỆU LIÊN QUAN

Nivolumab plus ipilimumab versus nivolumab in individuals with treatmentnaive programmed death-ligand 1 positive metastatic soft tissue sarcomas: A multicentre retrospective study

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: The INCREASE trial